Neurocognitive Outcomes in Clinical Trials for TSC and Related

download report

Transcript Neurocognitive Outcomes in Clinical Trials for TSC and Related

Outline
•
Significance
•
Definitions
•
Challenges
•
Next steps
Significance
•
Quality of Life
•
Safety
•
Efficacy/potentially modifiable
Definitions
•
What is neurocognition?
•
Inter-related levels of investigation
•
But need to be clear on what we are measuring
What to measure
•
Depth vs breadth
•
Inclusion criteria (make the most of each trial)
•
Across age/ability; validation
•
Multi-center: multiple cultures/languages
•
FDA-requirements: clinical vs regulatory
significance
Scientific Challenges
• Drug efficacy
– Mouse models: translating from mouse to man
– Predicting responders
– When and how long to treat
• Placebo-controlled, double blind trials needed
• Side effects of drug
– Risk/benefits in pediatric population
• Neurocognitive assessments
– Dynamic measures within timeframe of trial
– Standard battery across trials
Logistical challenges
• IRB and FDA requirements
• Multi-site enrollment for rare disorders
• Broad Infrastructure
– Recruitment, Patient safety, Monitoring, Data
management, Data analysis
• Funding
Next Steps - I
• Patient Based Outcome Measures
• In terms of FDA – f/u neuro-onco, epilepsy
trials etc.
• Stratify by epilepsy
• Younger age/adults/more severely affected
• Sleep/depression/anxiety
Next Steps - II
• Off-label use
• Education- importance of neurocog clinical
trials
• Biomarkers of cognition
• Funding